Glutamate cycle changes in the putamen of patients with de novo Parkinson's disease using 1H MRS

International audienceIntroduction: To investigate glutamatergic metabolism changes in the putamen of patients with de novo Parkin-son's Disease (PD) and test the hypothesis that glutamate (Glu) levels are abnormally elevated in the putamen contralateral to where the motor clinical signs predominate as expected from observations in animal models. Methods: H-1 NMR spectra from 17 healthy control volunteers were compared with spectra from 17 de novo PD patients of who 14 were evaluated again after 2-3 years of disease progression. Statistical analysis used random-effects models. Results: The only significant difference between PD patients and controls was a higher glutamine (Gln) con-centration in the putamen ipsilateral to the hemibody with predominant motor signs (Visit 1: 6.0 +/- 0.4 mM vs. 5.2 +/- 0.2 mM, p < 0.05; Visit 2: 6.2 +/- 0.3 mM vs. 5.2 +/- 0.2 mM, p < 0.05). At Visit 1, PD patients had higher Glu and Gln levels in the putamen ipsilateral versus contralateral to dominant clinical signs (Glu: 12.2 +/- 0.6 mM vs. 10.4 +/- 0.6 mM, p < 0.05; Gln: 6.0 +/- 0.4 mM vs. 4.8 +/- 0.4 mM, p < 0.05; Glu and Gln pool (Glx): 17.9 +/- 0.8 mM vs. 14.7 +/- 1.1 mM, p < 0.05). At Visit 2, the sum of the two metabolites remained significantly higher in the ipsilateral versus contralateral putamen (Glx: 18.3 +/- 0.6 mM vs. 16.1 +/- 0.9 mM, p < 0.05). Conclusion: In de novo PD patients, the putamen ipsilateral to the more affected hemibody showed elevated Gln versus controls and elevated Glu and Gln concentrations versus the contralateral side. Abnormalities in Glu metabolism therefore occur early in PD but unexpectedly in the putamen contralateral to the more damaged hemisphere, suggesting they are not dependent solely on dopamine loss

Le Parc Naturel Régional du Queyras vu par ses résidents permanents et secondaires

Cette note de synthèse présente les résultats de l'enquête par questionnaire réalisée auprès des résidents du périmètre du PNRQ (433 résidents permanents et 172 résidents secondaires). L'objectif est de proposer un éclairage sur leurs ressentis et leurs attentes concernant le PNRQ et son territoire

Translational view of an innovative tool for glioblastoma therapeutical strategy : 188 Re-SSS lipid nanocapsules

National audienc